Balentine LLC Has $386,000 Stock Holdings in UiPath Inc. (NYSE:PATH)

Balentine LLC raised its holdings in shares of UiPath Inc. (NYSE:PATH) by 6.1% in the 4th quarter, HoldingsChannel reports. The firm owned 15,553 shares of the healthcare company’s stock after buying an additional 889 shares during the period. Balentine LLC’s holdings in UiPath were worth $386,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in UiPath by 7.6% during the 3rd quarter. Vanguard Group Inc. now owns 37,750,773 shares of the healthcare company’s stock worth $645,916,000 after buying an additional 2,673,718 shares during the period. FMR LLC increased its position in UiPath by 2.9% during the 3rd quarter. FMR LLC now owns 16,238,176 shares of the healthcare company’s stock worth $277,835,000 after buying an additional 463,032 shares during the period. Norges Bank bought a new position in UiPath during the 4th quarter worth $165,749,000. Senvest Management LLC increased its position in UiPath by 3.0% during the 3rd quarter. Senvest Management LLC now owns 6,209,655 shares of the healthcare company’s stock worth $106,247,000 after buying an additional 181,722 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in UiPath by 2.3% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,301,413 shares of the healthcare company’s stock worth $131,687,000 after buying an additional 119,782 shares during the period. Institutional investors and hedge funds own 62.50% of the company’s stock.

UiPath Trading Down 2.0 %

UiPath stock opened at $19.90 on Wednesday. UiPath Inc. has a 12-month low of $13.30 and a 12-month high of $27.87. The business’s 50-day moving average price is $20.88 and its two-hundred day moving average price is $22.09.

UiPath (NYSE:PATH) last released its earnings results on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.10. UiPath had a negative return on equity of 3.29% and a negative net margin of 6.87%. The firm had revenue of $405.25 million for the quarter, compared to analysts’ expectations of $383.32 million. As a group, equities research analysts forecast that UiPath Inc. will post -0.04 EPS for the current year.

Analyst Ratings Changes

PATH has been the topic of several recent research reports. Needham & Company LLC reiterated a “buy” rating and set a $30.00 price objective on shares of UiPath in a research report on Wednesday, March 20th. Barclays increased their price objective on UiPath from $23.00 to $25.00 and gave the stock an “equal weight” rating in a research report on Friday, March 15th. Truist Financial restated a “buy” rating and issued a $32.00 price target on shares of UiPath in a research report on Wednesday, March 20th. Scotiabank raised their price target on UiPath from $29.00 to $30.00 and gave the stock a “sector perform” rating in a research report on Thursday, March 14th. Finally, Wells Fargo & Company raised their price target on UiPath from $24.00 to $25.00 and gave the stock an “equal weight” rating in a research report on Thursday, March 14th. Nine investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, UiPath presently has a consensus rating of “Moderate Buy” and a consensus target price of $27.41.

Insider Activity

In other news, CFO Ashim Gupta sold 40,000 shares of UiPath stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $21.66, for a total transaction of $866,400.00. Following the sale, the chief financial officer now directly owns 660,762 shares of the company’s stock, valued at $14,312,104.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders have sold 96,000 shares of company stock valued at $2,023,440. 22.37% of the stock is currently owned by corporate insiders.

UiPath Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.